{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-S5MGEUL7/1c0e7c78-3e7f-4a67-972c-753b29e2f238/HTML","dcterms:extent":"32 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-S5MGEUL7/b702cde1-2564-489d-a706-f091ce706b8b/PDF","dcterms:extent":"105 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-S5MGEUL7/a305ac3a-a113-42ec-8e6d-2d451a556696/TEXT","dcterms:extent":"28 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-S5MGEUL7","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2013","dc:creator":"Roškar, Robert","dc:format":[{"@xml:lang":"sl","#text":"številka:4"},{"@xml:lang":"sl","#text":"letnik:64"},{"@xml:lang":"sl","#text":"str. 281-287"}],"dc:identifier":["ISSN:0014-8229","COBISSID:3522161","URN:URN:NBN:SI:doc-S5MGEUL7"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"en","#text":"drug"},{"@xml:lang":"sl","#text":"interakcije"},{"@xml:lang":"sl","#text":"revmatična obolenja"},{"@xml:lang":"sl","#text":"zdravila"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Interakcije zdravil za zdravljenje revmatičnih bolezni| Interactions between drugs for treatment of rheumatic diseases|"},"dc:description":[{"@xml:lang":"sl","#text":"In this article interaction of drugs for treatment of rheumatic diseases are reviewed. For the most of these drugs a vast number of interactions have been described but only a minority with clinical importance. The majority of potentially relevant drug interactions exist for cyclosporine A, followed by methotrexate and non-steroidal anti-inflammatory drugs. Frequent and severe interactions in terms of adverse effects, sometimes with life-threatening consequences, occur in methotrexate and trimethoprim/sulfamethoxazole combination as well as in azathioprine and allopurinol comedication. Biological drugs do not show important interactions with other drugs. Treatment of rheumatic diseases is due to their nature commonly associated with polypharmacy, which increases the risk of drugdrug interactions, especially in elderly population with rheumatic diseases and other chronic illnesses"},{"@xml:lang":"sl","#text":"V prispevku je podan pregled interakcij zdravil za zdravljenje revmatičnih bolezni z drugimi zdravili. Za večino teh zdravil je opisanih mnogo interakcij, a le manjše število je klinično pomembnih. V največ relevantnih interakcij vstopa ciklosporin A, sledijo pa metotreksat in nesteroidni antirevmatiki. Pogoste in problematične interakcije v smislu neželenih učinkov, tudi življenjsko ogrožajočih, se pojavijo pri kombinacijah metotreksata in trimetoprim/sulfametoksazola ter azatioprina in alopurinola. Biološka zdravila nimajo pomembnejših interakcij z drugimi zdravili. Zdravljenje revmatičnih bolezni je zaradi narave obolenja pogosto povezano s polifarmakoterapijo, kar poveča tveganje za interakcije med zdravili, za kar so še posebej dovzetni starostniki in kronični bolniki s to boleznijo"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-S5MGEUL7","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-S5MGEUL7"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-S5MGEUL7/b702cde1-2564-489d-a706-f091ce706b8b/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-S5MGEUL7/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-S5MGEUL7"}}}}